QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=12E26BE49F608DA880933580566077C6;jsessionid=5353C91C979A6AA33181ABD6AD1C35EB;jsessionid=56378D3866873F9F333A9CD423514491;jsessionid=6F5A78B7D44784FBEE08277D995B20EA;jsessionid=D6B62E38B68E642CD00B6A271E375159;jsessionid=3C1A84306120B84723C0DF5C5CFECA7B (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=12E26BE49F608DA880933580566077C6;jsessionid=5353C91C979A6AA33181ABD6AD1C35EB;jsessionid=56378D3866873F9F333A9CD423514491;jsessionid=6F5A78B7D44784FBEE08277D995B20EA;jsessionid=D6B62E38B68E642CD00B6A271E375159;jsessionid=3C1A84306120B84723C0DF5C5CFECA7B